Dynavax’s lofty ambition to snatch Shingrix’s crown got off to a promising start after the biopharma’s investigational shingles vaccine held its own against GSK’s mainstay in the first part of a phase ...

Dynavax Technologies Corporation (NASDAQ:DVAX) surged 8% Thursday following the announcement of encouraging topline data from ...

Shares of Dynavax rose after the company released positive results from a trial of its shingles vaccine tested against current Shingles vaccine Shingrix. The stock was up 6.7% to $11.12 but is still ...

D ynavax Technologies has revealed promising topline outcomes from the initial part of its Phase I/II clinical trial, ...

Results from the first part of a Phase I/II trial (NCT06569823) showed that Z-1018 generated immune responses comparable to ...

Shares in Dynavax Technologies Corporation closed 5% higher Thursday after the presentation of positive top-line results from ...

Ryan Spencer, CEO of Dynavax, poses for a photo at the Dynavax office in Emeryville, Calif. on February 13, 2024.

Dynavax is pushing hard to make Heplisav-B standard of care in Hepatitis B, and pursue an opportunity to treat diabetes that could double the vaccine's addressable market from $300m, to $600m.

expand Dynavax CEO Ryan Spencer Adam Pardee By Ron Leuty – Senior Reporter, San Francisco Business Times Feb 20, 2025 Preview this article 1 min ...

The Emeryville, California-based biotech has just released topline results from a phase 1/2 head-to-head study comparing its ...

Dynavax's CpG 1018 adjuvant revenues have hit a brick wall. In Dynavax's halcyon days COVID was running hot and it sold its CpG 1018 adjuvant to diverse vaccine companies around the world.

Dynavax Technologies said on Thursday its experimental shingles vaccine generated a similar immune response as GSK's ...